ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Avastin (Bevacizumab) Biosimilars Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-0M9804
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Avastin Bevacizumab Biosimilars Market Research Report 2022
BUY CHAPTERS

Global Avastin (Bevacizumab) Biosimilars Market Research Report 2025

Code: QYRE-Auto-0M9804
Report
July 2025
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Genentech Inc
Pfizer Inc
Sartorius
Eli Lilly
Bayer
Amgen Inc
Samsung Bioepis
Cadila Pharmaceuticals
Dr. Reddy's
BIOCAD
mAbxience
Hetero
Biocon Ltd.
Mylan NV
BeiGene Ltd
Innovent
Qilu Pharmaceutical
Henlius
PlantForm
PharmaPraxis
Centus
Kirin Biologics
TOT BIOPHARM
Luye Pharmaceutical

Avastin (Bevacizumab) Biosimilars Market

The global market for Avastin (Bevacizumab) Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Avastin (Bevacizumab) is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
North American market for Avastin (Bevacizumab) Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Avastin (Bevacizumab) Biosimilars is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Avastin (Bevacizumab) Biosimilars include Roche, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen, PlantForm, PharmaPraxis, Samsung Bioepis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Avastin (Bevacizumab) Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Avastin (Bevacizumab) Biosimilars.
The Avastin (Bevacizumab) Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Avastin (Bevacizumab) Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Avastin (Bevacizumab) Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Avastin (Bevacizumab) Biosimilars Market Report

Report Metric Details
Report Name Avastin (Bevacizumab) Biosimilars Market
Segment by Type
  • Cancers
  • AMD
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen, PlantForm, PharmaPraxis, Samsung Bioepis, Centus, Cadila Pharmaceuticals, Dr Reddy's, Biocad, MAbxience, Hetero, Biocon, Kirin Biologics, Mylan, BeiGene, Innovent, Qilu Pharmaceutical, TOT BIOPHARM, Luye Pharmaceutical, Henlius
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Avastin (Bevacizumab) Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Avastin (Bevacizumab) Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Avastin (Bevacizumab) Biosimilars Market report?

Ans: The main players in the Avastin (Bevacizumab) Biosimilars Market are Roche, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen, PlantForm, PharmaPraxis, Samsung Bioepis, Centus, Cadila Pharmaceuticals, Dr Reddy's, Biocad, MAbxience, Hetero, Biocon, Kirin Biologics, Mylan, BeiGene, Innovent, Qilu Pharmaceutical, TOT BIOPHARM, Luye Pharmaceutical, Henlius

What are the Application segmentation covered in the Avastin (Bevacizumab) Biosimilars Market report?

Ans: The Applications covered in the Avastin (Bevacizumab) Biosimilars Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Avastin (Bevacizumab) Biosimilars Market report?

Ans: The Types covered in the Avastin (Bevacizumab) Biosimilars Market report are Cancers, AMD

1 Avastin (Bevacizumab) Biosimilars Market Overview
1.1 Product Definition
1.2 Avastin (Bevacizumab) Biosimilars by Type
1.2.1 Global Avastin (Bevacizumab) Biosimilars Market Value Comparison by Type (2024 VS 2031)
1.2.2 Cancers
1.2.3 AMD
1.3 Avastin (Bevacizumab) Biosimilars by Application
1.3.1 Global Avastin (Bevacizumab) Biosimilars Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Avastin (Bevacizumab) Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Avastin (Bevacizumab) Biosimilars Revenue 2020-2031
1.4.2 Global Avastin (Bevacizumab) Biosimilars Sales 2020-2031
1.4.3 Global Avastin (Bevacizumab) Biosimilars Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Avastin (Bevacizumab) Biosimilars Market Competition by Manufacturers
2.1 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Manufacturers (2020-2025)
2.2 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Avastin (Bevacizumab) Biosimilars Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Avastin (Bevacizumab) Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Avastin (Bevacizumab) Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Avastin (Bevacizumab) Biosimilars, Product Type & Application
2.7 Global Key Manufacturers of Avastin (Bevacizumab) Biosimilars, Date of Enter into This Industry
2.8 Global Avastin (Bevacizumab) Biosimilars Market Competitive Situation and Trends
2.8.1 Global Avastin (Bevacizumab) Biosimilars Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Avastin (Bevacizumab) Biosimilars Players Market Share by Revenue
2.8.3 Global Avastin (Bevacizumab) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Avastin (Bevacizumab) Biosimilars Market Scenario by Region
3.1 Global Avastin (Bevacizumab) Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2020-2031
3.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2020-2025
3.2.2 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2026-2031
3.3 Global Avastin (Bevacizumab) Biosimilars Revenue by Region: 2020-2031
3.3.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Region: 2020-2025
3.3.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Region: 2026-2031
3.4 North America Avastin (Bevacizumab) Biosimilars Market Facts & Figures by Country
3.4.1 North America Avastin (Bevacizumab) Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2031)
3.4.3 North America Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Avastin (Bevacizumab) Biosimilars Market Facts & Figures by Country
3.5.1 Europe Avastin (Bevacizumab) Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2031)
3.5.3 Europe Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Avastin (Bevacizumab) Biosimilars Market Facts & Figures by Region
3.6.1 Asia Pacific Avastin (Bevacizumab) Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Avastin (Bevacizumab) Biosimilars Sales by Region (2020-2031)
3.6.3 Asia Pacific Avastin (Bevacizumab) Biosimilars Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Avastin (Bevacizumab) Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Avastin (Bevacizumab) Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2031)
3.7.3 Latin America Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Avastin (Bevacizumab) Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Avastin (Bevacizumab) Biosimilars Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2031)
3.8.3 Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2020-2031)
4.1.1 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2020-2025)
4.1.2 Global Avastin (Bevacizumab) Biosimilars Sales by Type (2026-2031)
4.1.3 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2020-2031)
4.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2020-2031)
4.2.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2020-2025)
4.2.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Type (2026-2031)
4.2.3 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2020-2031)
4.3 Global Avastin (Bevacizumab) Biosimilars Price by Type (2020-2031)
5 Segment by Application
5.1 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2020-2031)
5.1.1 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2020-2025)
5.1.2 Global Avastin (Bevacizumab) Biosimilars Sales by Application (2026-2031)
5.1.3 Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2020-2031)
5.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2020-2031)
5.2.1 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2020-2025)
5.2.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Application (2026-2031)
5.2.3 Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2020-2031)
5.3 Global Avastin (Bevacizumab) Biosimilars Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Roche Avastin (Bevacizumab) Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Company Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Sartorius
6.4.1 Sartorius Company Information
6.4.2 Sartorius Description and Business Overview
6.4.3 Sartorius Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio
6.4.5 Sartorius Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Company Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Bayer
6.6.1 Bayer Company Information
6.6.2 Bayer Description and Business Overview
6.6.3 Bayer Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio
6.6.5 Bayer Recent Developments/Updates
6.7 Amgen
6.7.1 Amgen Company Information
6.7.2 Amgen Description and Business Overview
6.7.3 Amgen Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio
6.7.5 Amgen Recent Developments/Updates
6.8 PlantForm
6.8.1 PlantForm Company Information
6.8.2 PlantForm Description and Business Overview
6.8.3 PlantForm Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.8.4 PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio
6.8.5 PlantForm Recent Developments/Updates
6.9 PharmaPraxis
6.9.1 PharmaPraxis Company Information
6.9.2 PharmaPraxis Description and Business Overview
6.9.3 PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.9.4 PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio
6.9.5 PharmaPraxis Recent Developments/Updates
6.10 Samsung Bioepis
6.10.1 Samsung Bioepis Company Information
6.10.2 Samsung Bioepis Description and Business Overview
6.10.3 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio
6.10.5 Samsung Bioepis Recent Developments/Updates
6.11 Centus
6.11.1 Centus Company Information
6.11.2 Centus Description and Business Overview
6.11.3 Centus Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Centus Avastin (Bevacizumab) Biosimilars Product Portfolio
6.11.5 Centus Recent Developments/Updates
6.12 Cadila Pharmaceuticals
6.12.1 Cadila Pharmaceuticals Company Information
6.12.2 Cadila Pharmaceuticals Description and Business Overview
6.12.3 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio
6.12.5 Cadila Pharmaceuticals Recent Developments/Updates
6.13 Dr Reddy's
6.13.1 Dr Reddy's Company Information
6.13.2 Dr Reddy's Description and Business Overview
6.13.3 Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio
6.13.5 Dr Reddy's Recent Developments/Updates
6.14 Biocad
6.14.1 Biocad Company Information
6.14.2 Biocad Description and Business Overview
6.14.3 Biocad Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio
6.14.5 Biocad Recent Developments/Updates
6.15 MAbxience
6.15.1 MAbxience Company Information
6.15.2 MAbxience Description and Business Overview
6.15.3 MAbxience Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.15.4 MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio
6.15.5 MAbxience Recent Developments/Updates
6.16 Hetero
6.16.1 Hetero Company Information
6.16.2 Hetero Description and Business Overview
6.16.3 Hetero Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio
6.16.5 Hetero Recent Developments/Updates
6.17 Biocon
6.17.1 Biocon Company Information
6.17.2 Biocon Description and Business Overview
6.17.3 Biocon Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio
6.17.5 Biocon Recent Developments/Updates
6.18 Kirin Biologics
6.18.1 Kirin Biologics Company Information
6.18.2 Kirin Biologics Description and Business Overview
6.18.3 Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio
6.18.5 Kirin Biologics Recent Developments/Updates
6.19 Mylan
6.19.1 Mylan Company Information
6.19.2 Mylan Description and Business Overview
6.19.3 Mylan Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio
6.19.5 Mylan Recent Developments/Updates
6.20 BeiGene
6.20.1 BeiGene Company Information
6.20.2 BeiGene Description and Business Overview
6.20.3 BeiGene Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.20.4 BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio
6.20.5 BeiGene Recent Developments/Updates
6.21 Innovent
6.21.1 Innovent Company Information
6.21.2 Innovent Description and Business Overview
6.21.3 Innovent Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio
6.21.5 Innovent Recent Developments/Updates
6.22 Qilu Pharmaceutical
6.22.1 Qilu Pharmaceutical Company Information
6.22.2 Qilu Pharmaceutical Description and Business Overview
6.22.3 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
6.22.5 Qilu Pharmaceutical Recent Developments/Updates
6.23 TOT BIOPHARM
6.23.1 TOT BIOPHARM Company Information
6.23.2 TOT BIOPHARM Description and Business Overview
6.23.3 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.23.4 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio
6.23.5 TOT BIOPHARM Recent Developments/Updates
6.24 Luye Pharmaceutical
6.24.1 Luye Pharmaceutical Company Information
6.24.2 Luye Pharmaceutical Description and Business Overview
6.24.3 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
6.24.5 Luye Pharmaceutical Recent Developments/Updates
6.25 Henlius
6.25.1 Henlius Company Information
6.25.2 Henlius Description and Business Overview
6.25.3 Henlius Avastin (Bevacizumab) Biosimilars Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio
6.25.5 Henlius Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Avastin (Bevacizumab) Biosimilars Industry Chain Analysis
7.2 Avastin (Bevacizumab) Biosimilars Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Avastin (Bevacizumab) Biosimilars Production Mode & Process Analysis
7.4 Avastin (Bevacizumab) Biosimilars Sales and Marketing
7.4.1 Avastin (Bevacizumab) Biosimilars Sales Channels
7.4.2 Avastin (Bevacizumab) Biosimilars Distributors
7.5 Avastin (Bevacizumab) Biosimilars Customer Analysis
8 Avastin (Bevacizumab) Biosimilars Market Dynamics
8.1 Avastin (Bevacizumab) Biosimilars Industry Trends
8.2 Avastin (Bevacizumab) Biosimilars Market Drivers
8.3 Avastin (Bevacizumab) Biosimilars Market Challenges
8.4 Avastin (Bevacizumab) Biosimilars Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Roche
Genentech Inc
Pfizer Inc
Sartorius
Eli Lilly
Bayer
Amgen Inc
Samsung Bioepis
Cadila Pharmaceuticals
Dr. Reddy's
BIOCAD
mAbxience
Hetero
Biocon Ltd.
Mylan NV
BeiGene Ltd
Innovent
Qilu Pharmaceutical
Henlius
PlantForm
PharmaPraxis
Centus
Kirin Biologics
TOT BIOPHARM
Luye Pharmaceutical
List of Tables
 Table 1. Global Avastin (Bevacizumab) Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Avastin (Bevacizumab) Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Avastin (Bevacizumab) Biosimilars Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Avastin (Bevacizumab) Biosimilars Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Avastin (Bevacizumab) Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Avastin (Bevacizumab) Biosimilars Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Avastin (Bevacizumab) Biosimilars Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Avastin (Bevacizumab) Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Avastin (Bevacizumab) Biosimilars, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Avastin (Bevacizumab) Biosimilars, Product Type & Application
 Table 12. Global Key Manufacturers of Avastin (Bevacizumab) Biosimilars, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Avastin (Bevacizumab) Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Avastin (Bevacizumab) Biosimilars as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Avastin (Bevacizumab) Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2020-2025) & (K Units)
 Table 18. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2020-2025)
 Table 19. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2026-2031) & (K Units)
 Table 20. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2026-2031)
 Table 21. Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2020-2025)
 Table 23. Global Avastin (Bevacizumab) Biosimilars Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2026-2031)
 Table 25. North America Avastin (Bevacizumab) Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 27. North America Avastin (Bevacizumab) Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 28. North America Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Avastin (Bevacizumab) Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Avastin (Bevacizumab) Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Avastin (Bevacizumab) Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Avastin (Bevacizumab) Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Avastin (Bevacizumab) Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Avastin (Bevacizumab) Biosimilars Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Avastin (Bevacizumab) Biosimilars Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Avastin (Bevacizumab) Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Avastin (Bevacizumab) Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Avastin (Bevacizumab) Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Avastin (Bevacizumab) Biosimilars Sales (K Units) by Type (2020-2025)
 Table 51. Global Avastin (Bevacizumab) Biosimilars Sales (K Units) by Type (2026-2031)
 Table 52. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2020-2025)
 Table 53. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Type (2026-2031)
 Table 54. Global Avastin (Bevacizumab) Biosimilars Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Avastin (Bevacizumab) Biosimilars Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2020-2025)
 Table 57. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Type (2026-2031)
 Table 58. Global Avastin (Bevacizumab) Biosimilars Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Avastin (Bevacizumab) Biosimilars Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Avastin (Bevacizumab) Biosimilars Sales (K Units) by Application (2020-2025)
 Table 61. Global Avastin (Bevacizumab) Biosimilars Sales (K Units) by Application (2026-2031)
 Table 62. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2020-2025)
 Table 63. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Application (2026-2031)
 Table 64. Global Avastin (Bevacizumab) Biosimilars Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Avastin (Bevacizumab) Biosimilars Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2020-2025)
 Table 67. Global Avastin (Bevacizumab) Biosimilars Revenue Market Share by Application (2026-2031)
 Table 68. Global Avastin (Bevacizumab) Biosimilars Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Avastin (Bevacizumab) Biosimilars Price (USD/Unit) by Application (2026-2031)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Roche Avastin (Bevacizumab) Biosimilars Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Genentech Company Information
 Table 76. Genentech Description and Business Overview
 Table 77. Genentech Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Genentech Avastin (Bevacizumab) Biosimilars Product
 Table 79. Genentech Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer Avastin (Bevacizumab) Biosimilars Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Sartorius Company Information
 Table 86. Sartorius Description and Business Overview
 Table 87. Sartorius Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Sartorius Avastin (Bevacizumab) Biosimilars Product
 Table 89. Sartorius Recent Developments/Updates
 Table 90. Eli Lilly Company Information
 Table 91. Eli Lilly Description and Business Overview
 Table 92. Eli Lilly Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Eli Lilly Avastin (Bevacizumab) Biosimilars Product
 Table 94. Eli Lilly Recent Developments/Updates
 Table 95. Bayer Company Information
 Table 96. Bayer Description and Business Overview
 Table 97. Bayer Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Bayer Avastin (Bevacizumab) Biosimilars Product
 Table 99. Bayer Recent Developments/Updates
 Table 100. Amgen Company Information
 Table 101. Amgen Description and Business Overview
 Table 102. Amgen Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Amgen Avastin (Bevacizumab) Biosimilars Product
 Table 104. Amgen Recent Developments/Updates
 Table 105. PlantForm Company Information
 Table 106. PlantForm Description and Business Overview
 Table 107. PlantForm Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. PlantForm Avastin (Bevacizumab) Biosimilars Product
 Table 109. PlantForm Recent Developments/Updates
 Table 110. PharmaPraxis Company Information
 Table 111. PharmaPraxis Description and Business Overview
 Table 112. PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. PharmaPraxis Avastin (Bevacizumab) Biosimilars Product
 Table 114. PharmaPraxis Recent Developments/Updates
 Table 115. Samsung Bioepis Company Information
 Table 116. Samsung Bioepis Description and Business Overview
 Table 117. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product
 Table 119. Samsung Bioepis Recent Developments/Updates
 Table 120. Centus Company Information
 Table 121. Centus Description and Business Overview
 Table 122. Centus Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. Centus Avastin (Bevacizumab) Biosimilars Product
 Table 124. Centus Recent Developments/Updates
 Table 125. Cadila Pharmaceuticals Company Information
 Table 126. Cadila Pharmaceuticals Description and Business Overview
 Table 127. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product
 Table 129. Cadila Pharmaceuticals Recent Developments/Updates
 Table 130. Dr Reddy's Company Information
 Table 131. Dr Reddy's Description and Business Overview
 Table 132. Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. Dr Reddy's Avastin (Bevacizumab) Biosimilars Product
 Table 134. Dr Reddy's Recent Developments/Updates
 Table 135. Biocad Company Information
 Table 136. Biocad Description and Business Overview
 Table 137. Biocad Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 138. Biocad Avastin (Bevacizumab) Biosimilars Product
 Table 139. Biocad Recent Developments/Updates
 Table 140. MAbxience Company Information
 Table 141. MAbxience Description and Business Overview
 Table 142. MAbxience Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 143. MAbxience Avastin (Bevacizumab) Biosimilars Product
 Table 144. MAbxience Recent Developments/Updates
 Table 145. Hetero Company Information
 Table 146. Hetero Description and Business Overview
 Table 147. Hetero Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 148. Hetero Avastin (Bevacizumab) Biosimilars Product
 Table 149. Hetero Recent Developments/Updates
 Table 150. Biocon Company Information
 Table 151. Biocon Description and Business Overview
 Table 152. Biocon Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 153. Biocon Avastin (Bevacizumab) Biosimilars Product
 Table 154. Biocon Recent Developments/Updates
 Table 155. Kirin Biologics Company Information
 Table 156. Kirin Biologics Description and Business Overview
 Table 157. Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 158. Kirin Biologics Avastin (Bevacizumab) Biosimilars Product
 Table 159. Kirin Biologics Recent Developments/Updates
 Table 160. Mylan Company Information
 Table 161. Mylan Description and Business Overview
 Table 162. Mylan Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 163. Mylan Avastin (Bevacizumab) Biosimilars Product
 Table 164. Mylan Recent Developments/Updates
 Table 165. BeiGene Company Information
 Table 166. BeiGene Description and Business Overview
 Table 167. BeiGene Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 168. BeiGene Avastin (Bevacizumab) Biosimilars Product
 Table 169. BeiGene Recent Developments/Updates
 Table 170. Innovent Company Information
 Table 171. Innovent Description and Business Overview
 Table 172. Innovent Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 173. Innovent Avastin (Bevacizumab) Biosimilars Product
 Table 174. Innovent Recent Developments/Updates
 Table 175. Qilu Pharmaceutical Company Information
 Table 176. Qilu Pharmaceutical Description and Business Overview
 Table 177. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 178. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product
 Table 179. Qilu Pharmaceutical Recent Developments/Updates
 Table 180. TOT BIOPHARM Company Information
 Table 181. TOT BIOPHARM Description and Business Overview
 Table 182. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 183. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product
 Table 184. TOT BIOPHARM Recent Developments/Updates
 Table 185. Luye Pharmaceutical Company Information
 Table 186. Luye Pharmaceutical Description and Business Overview
 Table 187. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 188. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product
 Table 189. Luye Pharmaceutical Recent Developments/Updates
 Table 190. Henlius Company Information
 Table 191. Henlius Description and Business Overview
 Table 192. Henlius Avastin (Bevacizumab) Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 193. Henlius Avastin (Bevacizumab) Biosimilars Product
 Table 194. Henlius Recent Developments/Updates
 Table 195. Key Raw Materials Lists
 Table 196. Raw Materials Key Suppliers Lists
 Table 197. Avastin (Bevacizumab) Biosimilars Distributors List
 Table 198. Avastin (Bevacizumab) Biosimilars Customers List
 Table 199. Avastin (Bevacizumab) Biosimilars Market Trends
 Table 200. Avastin (Bevacizumab) Biosimilars Market Drivers
 Table 201. Avastin (Bevacizumab) Biosimilars Market Challenges
 Table 202. Avastin (Bevacizumab) Biosimilars Market Restraints
 Table 203. Research Programs/Design for This Report
 Table 204. Key Data Information from Secondary Sources
 Table 205. Key Data Information from Primary Sources
 Table 206. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Avastin (Bevacizumab) Biosimilars
 Figure 2. Global Avastin (Bevacizumab) Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Avastin (Bevacizumab) Biosimilars Market Share by Type: 2024 & 2031
 Figure 4. Cancers Product Picture
 Figure 5. AMD Product Picture
 Figure 6. Global Avastin (Bevacizumab) Biosimilars Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Avastin (Bevacizumab) Biosimilars Market Share by Application: 2024 & 2031
 Figure 8. Hospitals
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Avastin (Bevacizumab) Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Avastin (Bevacizumab) Biosimilars Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Avastin (Bevacizumab) Biosimilars Sales (2020-2031) & (K Units)
 Figure 14. Global Avastin (Bevacizumab) Biosimilars Average Price (USD/Unit) & (2020-2031)
 Figure 15. Avastin (Bevacizumab) Biosimilars Report Years Considered
 Figure 16. Avastin (Bevacizumab) Biosimilars Sales Share by Manufacturers in 2024
 Figure 17. Global Avastin (Bevacizumab) Biosimilars Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Avastin (Bevacizumab) Biosimilars Players: Market Share by Revenue in Avastin (Bevacizumab) Biosimilars in 2024
 Figure 19. Avastin (Bevacizumab) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Avastin (Bevacizumab) Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2020-2031)
 Figure 22. North America Avastin (Bevacizumab) Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 23. United States Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2020-2031)
 Figure 26. Europe Avastin (Bevacizumab) Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Avastin (Bevacizumab) Biosimilars Revenue Market Share by Region (2020-2031)
 Figure 34. China Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Avastin (Bevacizumab) Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Avastin (Bevacizumab) Biosimilars Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Avastin (Bevacizumab) Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Avastin (Bevacizumab) Biosimilars by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Avastin (Bevacizumab) Biosimilars by Type (2020-2031)
 Figure 55. Global Avastin (Bevacizumab) Biosimilars Price (USD/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Avastin (Bevacizumab) Biosimilars by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Avastin (Bevacizumab) Biosimilars by Application (2020-2031)
 Figure 58. Global Avastin (Bevacizumab) Biosimilars Price (USD/Unit) by Application (2020-2031)
 Figure 59. Avastin (Bevacizumab) Biosimilars Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Bevacizumab Market Insights Forecast to 2030
Global Bevacizumab Generics Market Research Report 2024
Avastin Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Bevacizumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biosimilar Bevacizuma Market Research Report 2024
Lucentis Ranibizumab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Global Raibizumab Biosimilars Market Research Report 2025
Oncology Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti VEGF Intravitreal Drugs Market Research Report 2024
Global Anti VEGF Therapy for Cancer Market Research Report 2024
Global Intravitreal Injection of Anti VEGF Drugs Market Research Report 2024
Global Anti VEGT Drugs Market Research Report 2024
Global VEGF A Inhibitor Market Research Report 2024
Global Ranibizumab Injection Market Research Report 2024
Global Intravitreal Injection Market Research Report 2024
Global Monoclonal Antibody Anti VEGF Ophthalmic Drugs Market Research Report 2024
Bevacizumab Biosimilar Market
Global Rituximab Biosimilars Market Research Report 2025
Global Anti VEGF Therapeutic Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions